Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0120)
Name
D-Glucose
Synonyms
D-Glc; D-Glucopyranose; D-Glucopyranoside; D-Glucose; Glc; Glucopyranose; Glucopyranoside; Glucose; 2280-44-6; Grape sugar; D-Glcp; (3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; Glucosum, anhydrous; CHEBI:4167; 54-17-1; GLUCOSE, ALPHA-D-; rel-(3R,4S,5S,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; DTXSID901015217; Glucopyranose, D-; (3R,4S,5S,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; Glucodin; Meritose; Blood sugar; Clintose L; D-gluco-hexose; CPC hydrate; Roferose ST; Clearsweet 95; a-D-Glucopyranose; Staleydex 95M; (+)-Glucose; UNII-5J5I9EB41E; 2h-pyran-2,3,4,5-tetraol; D-Glucopyranose, anhydrous; DTXSID30197710; glc-ring; EINECS 207-757-8; Cartose Cerelose; D-glucose-ring; Glucose injection; Glucose 40; Staleydex 130; EINECS 218-914-5; Glc-OH; Meritose 200; nchembio867-comp4; Glucose (JP17); starbld0000491; 6-(hydroxymethyl)tetrahydropyran-2,3,4,5-tetraol; Anhydrous Glucose ,(S); Purified glucose (JP17); Epitope ID:142342; D-(+)-DEXTROSE; GTPL4536; CHEMBL1222250; BDBM34103; CHEBI:37661; DTXCID90120201; WQZGKKKJIJFFOK-GASJEMHNSA-N; DTXCID201473543; DTXSID501015215; 26655-34-5; AKOS025147374; NSC 287045; NCGC00166293-01; BS-48662; G0048; (3R,4S,5S,6R)-6-(hydroxymethyl)tetrahydro-; C00031; D00009; F71542; Q37525; Q23905964; N_FULL/O_FULL_10000000000000_GS_656; D-glucose (closed ring structure, complete stereochemistry); WURCS=2.0/1,1,0/(a2122h-1a_1-5)/1/

    Click to Show/Hide
Structure
Formula
C6H12O6
IUPAC Name
(3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
Canonical SMILES
C(C1C(C(C(C(O1)O)O)O)O)O
InChI
InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5-,6?/m1/s1
InChIKey
WQZGKKKJIJFFOK-GASJEMHNSA-N
PubChem CID
5793
Full List of Ferroptosis Target Related to This Drug
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
 Target Info 
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Chronic kidney disease ICD-11: GB61
 Disease Info 
Responsed Regulator High mobility group protein B1 (HMGB1) Driver
 Regulator Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
NF-kappa B signaling pathway hsa04064
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model SV40 MES 13 cells Normal Mus musculus CVCL_5368
Response regulation Erastin and high glucose both induced ferroptosis in mesangial cells. Suppression of HMGB1 restored cellular proliferation, prevented ROS and LDH generation, decreased ACSL4, PTGS2, and NOX1, and increased GPX4 levels in mesangial cells. Furthermore, nuclear factor E2-related factor 2 (Nrf2) was decreased in diabetic nephropathy (DN) patients and high glucose-mediated translocation of HMGB1 in mesangial cells.
References
Ref 1 HMGB1 regulates ferroptosis through Nrf2 pathway in mesangial cells in response to high glucose. Biosci Rep. 2021 Feb 26;41(2):BSR20202924. doi: 10.1042/BSR20202924.